Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies-Reference-Cited by-同舟云学术

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies

Published:2020-04-07 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Moentenich Valeska¹^ORCID,Gebauer Florian²,Comut Erdem³,Tuchscherer Armin¹,Bruns Christiane²,Schroeder Wolfgang²,Buettner Reinhard⁴,Alakus Hakan²,Loeser Heike⁴,Zander Thomas¹,Quaas Alexander⁴

Affiliation:

1. Department of Oncology and Hematology, University of Cologne, D‑50937 Cologne, Germany

2. Department of Visceral Surgery, University of Cologne, D‑50937 Cologne, Germany

3. Institute of Pathology, University of Cologne, D‑50937 Cologne, Germany

4. Institute of Pathology, Pammukale University, Denizli 20160, Turkey

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence;Translational Oncology;2024-09

2. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma;Gastric Cancer;2024-07-02

3. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma;The Annals of Thoracic Surgery;2024-07

4. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer;Expert Opinion on Drug Discovery;2024-06-26

5. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer;Digestive Diseases and Sciences;2024-05-20